Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Tompkins, Van S ^a   Han, Seong Su ^a   Olivier, Alicia ^a   Syrbu, Sergei ^a,c   Bair, Thomas ^a   Button, Anna ^b   Jacobus, Laura ^a,c   Wang, Zebin ^d   Lifton, Samuel ^a,e   Raychaudhuri, Pradip ^d   Morse III, Herbert C ^f   Weiner, George ^a,c   Link, Brian ^a,c   Smith, Brian J ^b,c   Janz, Siegfried ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e University of Iowa   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FOXM1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONTROLLED STUDY; FOXM1 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; TRANSGENIC MOUSE; TUMOR GENE;

ANIMALS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; SPECIES SPECIFICITY; THIOSTREPTON;

EID: 84885126448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076889     Document Type: Article

References (66)

1. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, et al. (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36: 1306-1311. doi:10.1038/ng1481. PubMed: 15565109.
2. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL, (2005) Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 26: 1343-1353. doi:10.1093/carcin/bgi100. PubMed: 15845649.
3. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, et al. (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48-55. PubMed: 15608639.
4. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238. doi:10.1016/S1535-6108(03)00197-1. PubMed: 14522256.
5. Gaspar C, Cardoso J, Franken P, Molenaar L, Morreau H, et al. (2008) Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol 172: 1363-1380. doi:10.2353/ajpath.2008.070851. PubMed: 18403596.
6. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, et al. (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125: 1269-1281. doi:10.1016/j.cell.2006.06.008. PubMed: 16814714.
7. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, et al. (2007) Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21: 1382-1395. doi:10.1101/gad.1545007. PubMed: 17510286.
8. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, et al. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-971. doi:10.1038/nature05886. PubMed: 17515920.
9. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303. doi:10.1038/nature10351. PubMed: 21796119.
10. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, et al. (2012) Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119: 2844-2853. doi:10.1182/blood-2011-10-388538. PubMed: 22323454.
11. Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21: 723-737. doi:10.1016/j.ccr.2012.05.024. PubMed: 22698399.
12. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, et al. (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14: 2131-2138. PubMed: 8683246.
13. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, et al. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537. doi:10.1182/blood-2009-05-220095. PubMed: 19704118.
14. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS, (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 3: 189-201. doi:10.1002/gcc.2870030304. PubMed: 1868033.
15. Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, et al. (2012) Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 119: 1882-1887. doi:10.1182/blood-2011-10-388470. PubMed: 22238326.
16. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, et al. (2005) Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 65: 1306-1315. doi:10.1158/0008-5472.CAN-04-0268. PubMed: 15735016.
17. Janz S, (2006) Myc translocations in B cell and plasma cell neoplasms. DNA Repair 5: 1213-1224. doi:10.1016/j.dnarep.2006.05.017. PubMed: 16815105.
18. Lenz G, Wright G, Dave SS, Xiao W, Powell J, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313-2323. doi:10.1056/NEJMoa0802885. PubMed: 19038878.
19. Janz S, Morse HC iii, Teitell MA, (2008) Mouse models of human mature B cell and plasma cell neoplasms. In: Li S, eds. Mouse models of human blood cancers. Springer Verlag. pp. pp. 179-225.
20. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92. doi:10.1038/nature08638. PubMed: 20054396.
21. Gusarova GA, Wang IC, Major ML, Kalinichenko VV, Ackerson T, et al. (2007) A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 117: 99-111. doi:10.1172/JCI27527. PubMed: 17173139.
22. Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, et al. (2003) Cyclin G1 Has Growth Inhibitory Activity Linked to the ARF-Mdm2-p53 and pRb Tumor Suppressor Pathways. Mol Cancer Res 1: 195-206. PubMed: 12556559.
23. Rhodes DR, Chinnaiyan AM, (2004) Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. Ann N Y Acad Sci 1020: 32-40. doi:10.1196/annals.1310.005. PubMed: 15208181.
24. Snel B, Lehmann G, Bork P, Huynen MA, (2000) STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res 28: 3442-3444. doi:10.1093/nar/28.18.3442. PubMed: 10982861.
25. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. doi:10.1101/gr.1239303. PubMed: 14597658.
26. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, et al. (2009) PID: the pathway interaction database. Nucleic Acids Res 37: D674-D679. doi:10.1093/nar/gkn653. PubMed: 18832364.
27. Huang DW, Sherman BT, Lempicki RA, (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57. doi:10.1038/nprot.2008.211. PubMed: 19131956.
28. Lenburg ME, Sinha A, Faller DV, Denis GV, (2007) Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem 282: 4803-4811. PubMed: 17166848.
29. Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, et al. (2006) Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A 103: 3304-3309. doi:10.1073/pnas.0511137103. PubMed: 16492737.
30. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511. doi:10.1038/35000501. PubMed: 10676951.
31. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390. doi:10.1038/ng1532. PubMed: 15778709.
32. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, et al. (2002) Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 99: 8886-8891. doi:10.1073/pnas.132253599. PubMed: 12077300.
33. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68-74. doi:10.1038/nm0102-68. PubMed: 11786909.
34. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431-2442. doi:10.1056/NEJMoa055759. PubMed: 16760443.
35. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430. doi:10.1056/NEJMoa055351. PubMed: 16760442.
36. Andréasson U, Dictor M, Jerkeman M, Berglund M, Sundström C, et al. (2009) Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol 84: 803-808. doi:10.1002/ajh.21549. PubMed: 19844990.
37. Chen X, Müller GA, Quaas M, Fischer M, Han N, et al. (2013) The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding Mechanism. Mol Cell Biol 33: 227-236. doi:10.1128/MCB.00881-12. PubMed: 23109430.
38. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, et al. (2011) Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 50: 313-326. doi:10.1002/gcc.20856. PubMed: 21305641.
39. Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, et al. (2012) Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 97: 1092-1100. doi:10.3324/haematol.2011.053421. PubMed: 22271891.
40. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S, (2011) The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 3: 725-731. doi:10.1038/nchem.1114. PubMed: 21860463.
41. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, et al. (2005) Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894. doi:10.1128/MCB.25.24.10875-10894.2005. PubMed: 16314512.
42. Bhat UG, Halasi M, Gart et al, (2009) FoxM1 Is a General Target for Proteasome Inhibitors. PLOS ONE 4: e6593. doi:10.1371/journal.pone.0006593. PubMed: 19672316.
43. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, et al. (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18: 830-850. doi:10.1101/gad.1200704. PubMed: 15082532.
44. Koo C-Y, Muir KW, Lam EWF, (2012) FOXM1: From cancer initiation to progression and treatment. Biochimica et Biophysica. Acta (BBA)- Gene Regulatory Mechanisms 1819: 28-37.
45. Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, et al. (2010) Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 36: 151-156. doi:10.1016/j.ctrv.2009.11.006. PubMed: 20022709.
46. Laoukili J, Stahl M, Medema RH, (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102. PubMed: 17014965.
47. Wonsey DR, Follettie MT, (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65: 5181-5189. doi:10.1158/0008-5472.CAN-04-4059. PubMed: 15958562.
48. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 109: 3879-3884. doi:10.1073/pnas.1121343109. PubMed: 22343534.
49. Horn H, Ziepert M, Becher C, Barth TFE, Bernd HW, et al. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121: 2253-2263. doi:10.1182/blood-2012-06-435842. PubMed: 23335369.
50. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129. doi:10.1101/gad.1067003. PubMed: 12695333.
51. Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, et al. (2008) C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology 48: 1302-1311. doi:10.1002/hep.22475. PubMed: 18798339.
52. Wierstra I, Alves J, (2006) FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2. FEBS J 273: 4645-4667. doi:10.1111/j.1742-4658.2006.05468.x. PubMed: 16965535.
53. Dai Y, Tang Y, He F, Zhang Y, Cheng A, et al. (2012) Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts. Virol J 9: 77. doi:10.1186/1743-422X-9-77. PubMed: 22458412.
54. Akyurek N, Drakos E, Giaslakiotis K, Knoblock RJ, Abruzzo LV, et al. (2010) Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma. Hum Pathol 41: 1448-1455. doi:10.1016/j.humpath.2010.04.001. PubMed: 20688354.
55. Frontini M, Kukalev A, Leo E, Ng YM, Cervantes M, et al. (2012) The CDK subunit CKS2 counteracts CKS1 to control cyclin A/CDK2 activity in maintaining replicative fidelity and neurodevelopment. Dev Cell 23: 356-370. doi:10.1016/j.devcel.2012.06.018. PubMed: 22898779.
56. Clark MC, Pang M, Hsu DK, Liu FT, de Vos S, et al. (2012) Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120: 4635-4644. doi:10.1182/blood-2012-06-438234. PubMed: 23065155.
57. Hsu PL, Hsu SM, (1998) Abundance of Heat Shock Proteins (hsp89, hsp60, and hsp27) in Malignant Cells of Hodgkin's Disease. Cancer Res 58: 5507-5513. PubMed: 9850087.
58. Ghosh JC, Dohi T, Kang BH, Altieri DC, (2008) Hsp60 Regulation of Tumor Cell Apoptosis. J Biol Chem 283: 5188-5194. PubMed: 18086682.
59. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, et al. (2000) Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97: 3260-3265. doi:10.1073/pnas.97.7.3260. PubMed: 10737792.
60. Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, et al. (2000) Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc Natl Acad Sci USA 97: 2680-2685. doi:10.1073/pnas.97.6.2680. PubMed: 10716996.
61. Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, et al. (2012) An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer. PLOS ONE 7: e47086. doi:10.1371/journal.pone.0047086. PubMed: 23056589.
62. Grantham J, Brackley KI, Willison KR, (2006) Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp Cell Res 312: 2309-2324. doi:10.1016/j.yexcr.2006.03.028. PubMed: 16765944.
63. Nadler-Holly M, Breker M, Gruber R, Azia A, Gymrek M, et al. (2012) Interactions of subunit CCT3 in the yeast chaperonin CCT/TRiC with Q/N-rich proteins revealed by high-throughput microscopy analysis. Proc Natl Acad Sci USA 109: 18833-18838. doi:10.1073/pnas.1209277109. PubMed: 23112166.
64. Mancina RM, Burza MA, Maglio C, Pirazzi C, Sentinelli F, et al. (2013) The COBLL1 C allele is associated with lower serum insulin levels and lower insulin resistance in overweight and obese children. Diabetes/Metab Res Rev 29: 413-416. doi:10.1002/dmrr.2408. PubMed: 23463496.
65. Kass DJ, (2011) Cytokine-like factor 1 (CLF1): Life after development? Cytokine 55: 325-329. doi:10.1016/j.cyto.2011.05.021. PubMed: 21715184.
66. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 111: 3701-3713. doi:10.1182/blood-2007-09-111948. PubMed: 18160665.